Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Itolizumab · 1 trial · 2 indications
Number of participants with treatment-related adverse events as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0.
| Arm | Type | Description |
|---|---|---|
| EQ001 Type A cohort | EXPERIMENTAL | EQ001 administered in an unblinded dose escalating cohort fashion by subcutaneous injection every two weeks for a total of 2 doses (up to 5 cohorts with dosing to be determined in the range of 0.4 -- 3.2 mg/kg). |
| EQ001 for Type B cohort | EXPERIMENTAL | EQ001 administered in an unblinded single dose cohort by subcutaneous injection every two weeks for a total of 13 doses (1.6 mg/kg). |
| Name | Type | Description |
|---|---|---|
| Itolizumab [Bmab 600] | DRUG | EQ001 |
Type A Cohort Key Inclusion Criteria: 1. Is male or female, age ≥ 18 and ≤ 75 years 2. Has previously been documented to have met or currently meets Systemic Lupus International Collaborating Clinics (SLICC) and/or American College of Rheumatology (ACR) criteria for SLE 3. Received at least 1 immun...
Top 20 of 32 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Biogen Inc. | BIIB | 5 | PHASE3 | Litifilimab |
| Bristol-Myers Squibb Company | BMY | 7 | PHASE3 | Deucravacitinib |
| Viatris, Inc. | VTRS | 5 | PHASE3 | Cenerimod |
| Novartis AG Sponsored ADR | NVS | 7 | PHASE3 | Ianalumab |
| AstraZeneca PLC | AZN | 21 | PHASE3 | Medi-546 |
| Johnson & Johnson | JNJ | 1 | PHASE3 | Nipocalimab |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Upadacitinib |
| GSK plc Sponsored ADR | GSK | 3 | PHASE2 | Belimumab |
| Sanofi SA Sponsored ADR | SNY | 2 | PHASE2 | SAR441344 |
| Zenas BioPharma, Inc. | ZBIO | 1 | PHASE2 | Obexelimab |
| Alumis Inc. | ALMS | 1 | PHASE2 | Envudeucitinib |
| Immunovant Inc | IMVT | 1 | PHASE2 | IMVT-1402 |
| Amgen Inc. | AMGN | 1 | PHASE2 | Inebilizumab, Blinatumomab |
| Fate Therapeutics, Inc. | FATE | 2 | PHASE2 | FT819 |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY4298445 |
| Cartesian Therapeutics, Inc. | RNAC | 2 | PHASE2 | Descartes-08 |
| Merck & Co., Inc. | MRK | 1 | PHASE1 | MK-1045 |
| Gilead Sciences, Inc. | GILD | 1 | PHASE1 | KITE-363, Fludarabine, Cyclophosphamide |
| Artiva Biotherapeutics, Inc. | ARTV | 2 | PHASE1 | AB-101, Cyclophosphamide, Fludarabine, Rituximab, Obinutuzumab |
| Cullinan Therapeutics, Inc. | CGEM | 1 | PHASE1 | CLN-978 |
Itolizumab is an investigational small molecule being studied for the treatment of Lupus Erythematosus, including systemic lupus erythematosus with or without active proliferative nephritis. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
Itolizumab is a small molecule that targets a specific molecular pathway involved in the immune response. It is being developed for the treatment of Lupus Erythematosus, a condition characterized by abnormal immune system activity.
Itolizumab is being developed by Equillium, Inc., a biopharmaceutical company. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with Lupus Erythematosus.
Itolizumab is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The drug is still being studied in clinical trials to assess its safety and potential therapeutic effects.
Itolizumab has been studied in one completed clinical trial, NCT04128579, which evaluated the drug in patients with systemic lupus erythematosus with or without active proliferative nephritis. The trial enrolled 52 participants and was conducted in the United States, India, and Poland.
Yes, Itolizumab is also known as EQ001. The clinical trial NCT04128579, which studied the drug in systemic lupus erythematosus, refers to it as EQ001 (Itolizumab).